

# Giulio Fortuna

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1271302/publications.pdf>

Version: 2024-02-01

62  
papers

1,313  
citations

430874

18  
h-index

377865

34  
g-index

62  
all docs

62  
docs citations

62  
times ranked

1727  
citing authors

#	ARTICLE	IF	CITATIONS
1	Linear immunoglobulin A bullous dermatosis. <i>Clinics in Dermatology</i> , 2012, 30, 38-50.	1.6	170
2	Systemic Lupus Erythematosus. <i>Dental Clinics of North America</i> , 2013, 57, 631-655.	1.8	144
3	Mucormycosis in immunocompetent patients: a case-series of patients with maxillary sinus involvement and a critical review of the literature. <i>International Journal of Infectious Diseases</i> , 2011, 15, e533-e540.	3.3	90
4	Anxiety, Depression, and Pain in Burning Mouth Syndrome: First Chicken or Egg?. <i>Headache</i> , 2012, 52, 1019-1025.	3.9	90
5	Dysgeusia in COVID-19: Possible Mechanisms and Implications. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2020, 130, 344-346.	0.4	90
6	A critical reappraisal of the current data on drug-induced linear immunoglobulin A bullous dermatosis: A real and separate nosological entity?. <i>Journal of the American Academy of Dermatology</i> , 2012, 66, 988-994.	1.2	81
7	The usefulness of YouTube™ videos as a source of information on burning mouth syndrome. <i>Journal of Oral Rehabilitation</i> , 2019, 46, 657-665.	3.0	37
8	Assessment of oral health-related quality of life, measured by OHIP-14 and GOHAI, and psychological profiling in burning mouth syndrome: A case-control clinical study. <i>Journal of Oral Rehabilitation</i> , 2020, 47, 42-52.	3.0	35
9	Nikolsky's Sign on the Gingival Mucosa: A Clinical Tool for Oral Health Practitioners. <i>Journal of Periodontology</i> , 2008, 79, 2241-2246.	3.4	32
10	Drug-induced oral lichenoid reactions: a real clinical entity? A systematic review. <i>European Journal of Clinical Pharmacology</i> , 2017, 73, 1523-1537.	1.9	32
11	Unexplained somatic comorbidities in patients with burning mouth syndrome: a controlled clinical study. <i>Journal of Orofacial Pain</i> , 2011, 25, 131-40.	1.7	32
12	Epidermolysis Bullosa Oropharyngeal Severity (EBOS) score: A multicenter development and reliability assessment. <i>Journal of the American Academy of Dermatology</i> , 2013, 68, 83-92.	1.2	28
13	Pro-Inflammatory Chemokines and Cytokines Dominate the Blister Fluid Molecular Signature in Patients with Epidermolysis Bullosa and Affect Leukocyte and Stem Cell Migration. <i>Journal of Investigative Dermatology</i> , 2017, 137, 2298-2308.	0.7	27
14	Lichen planus pemphigoides, a possible example of epitope spreading. <i>Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics</i> , 2010, 109, 837-843.	1.4	26
15	Burning Mouth Syndrome Responsive to Duloxetine: A Case Report: Table 1. <i>Pain Medicine</i> , 2011, 12, 466-469.	1.9	25
16	Complex oral sensitivity disorder: a reappraisal of current classification of burning mouth syndrome. <i>Oral Diseases</i> , 2013, 19, 730-732.	3.0	23
17	Frictional Keratoses on the Facial Attached Gingiva Are Rare Clinical Findings and Do Not Belong to the Category of Leukoplakia. <i>Journal of Oral and Maxillofacial Surgery</i> , 2011, 69, 1367-1374.	1.2	22
18	Oropharyngeal Pemphigus Vulgaris and Clinical Remission. <i>American Journal of Clinical Dermatology</i> , 2010, 11, 137-145.	6.7	21

#	ARTICLE	IF	CITATIONS
19	Multiple myeloma vs. breast cancer patients with bisphosphonates-related osteonecrosis of the jaws: a comparative analysis of response to treatment and predictors of outcome. <i>Journal of Oral Pathology and Medicine</i> , 2012, 41, 222-228.	2.7	16
20	Clinical behaviour and long-term therapeutic response in orofacial granulomatosis patients treated with intralesional triamcinolone acetonide injections alone or in combination with topical pimecrolimus 1%. <i>Journal of Oral Pathology and Medicine</i> , 2013, 42, 73-81.	2.7	15
21	Measuring quality of life in epidermolysis bullosa in Mexico: Cross-cultural validation of the Hispanic version of the Quality of Life in Epidermolysis Bullosa questionnaire. <i>Journal of the American Academy of Dermatology</i> , 2013, 69, 652-653.	1.2	15
22	Global research trends in complex oral sensitivity disorder: A systematic bibliometric analysis of the framework. <i>Journal of Oral Pathology and Medicine</i> , 2020, 49, 555-564.	2.7	15
23	Patterns of oral mucosa lesions in patients with epidermolysis bullosa: comparison and agreement between oral medicine and dermatology. <i>Journal of Oral Pathology and Medicine</i> , 2013, 42, 733-740.	2.7	14
24	Oral Crohn's Disease: A Favorable Clinical Response With Delayed-Release Triamcinolone Acetonide Intralesional Injections. <i>American Journal of Gastroenterology</i> , 2008, 103, 2954-2955.	0.4	13
25	Secondary syphilis mimicking pemphigus vulgaris. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2009, 23, 479-480.	2.4	12
26	Global research trends in complex oral sensitivity disorder: A systematic bibliometric analysis of the structures of knowledge. <i>Journal of Oral Pathology and Medicine</i> , 2020, 49, 565-579.	2.7	12
27	Small-Cell Lung Cancer and Necrolytic Migratory Erythema. <i>New England Journal of Medicine</i> , 2008, 359, 2731-2732.	27.0	11
28	Role of dystrophic epidermolysis bullosa in anxiety, depression and self-esteem: A controlled cross-sectional study. <i>Journal of Dermatology</i> , 2016, 43, 70-78.	1.2	11
29	Management of reticular oral lichen planus patients with burning mouth syndrome-like oral symptoms: a pilot study. <i>Journal of Dermatological Treatment</i> , 2018, 29, 623-629.	2.2	11
30	Clinical features of gingival lesions in patients with dystrophic epidermolysis bullosa: a cross-sectional study. <i>Australian Dental Journal</i> , 2015, 60, 18-23.	1.5	10
31	Variations in Serum Hemoglobin, Albumin, and Electrolytes in Patients Receiving Intravenous Immunoglobulin Therapy. <i>American Journal of Clinical Dermatology</i> , 2007, 8, 291-299.	6.7	9
32	Capecitabine-induced stomatitis: a likely pathogenetic mechanism of oral lichenoid mucositis. <i>European Journal of Clinical Pharmacology</i> , 2009, 65, 1057-1059.	1.9	9
33	Metastatic prostate cancer presenting as paraneoplastic pemphigus: a favourable clinical response to combined androgen blockade and conventional immunosuppressive therapy. <i>British Journal of Dermatology</i> , 2009, 160, 468-470.	1.5	9
34	Drug-induced burning mouth syndrome: a new clinico-pathological entity?. <i>Journal of Headache and Pain</i> , 2012, 13, 685-686.	6.0	9
35	Pain in Patients with Dystrophic Epidermolysis Bullosa: Association with Anxiety and Depression. <i>Psychiatry Investigation</i> , 2017, 14, 746.	1.6	9
36	Patched homolog 1 gene mutation (p.G1093R) induces nevoid basal cell carcinoma syndrome and non-syndromic keratocystic odontogenic tumors: A case report. <i>Oncology Letters</i> , 2012, 4, 241-244.	1.8	8

#	ARTICLE	IF	CITATIONS
37	The largest family of the Americas with dominant dystrophic epidermolysis bullosa pruriginosa: A 18-year longitudinal genotype-phenotype study. <i>Journal of Dermatological Science</i> , 2013, 71, 217-221.	1.9	8
38	Autoimmune mucocutaneous blistering diseases in the south of Italy: a 25-year retrospective study on 169 patients. <i>Journal of Oral Pathology and Medicine</i> , 2020, 49, 672-680.	2.7	8
39	Oral histoplasmosis of a healthy man in a non-endemic area. <i>Infection</i> , 2011, 39, 497-498.	4.7	7
40	Comment: Probable Clindamycin-Induced Ageusia, Xerostomia, and Burning Mouth Syndrome. <i>Annals of Pharmacotherapy</i> , 2012, 46, 1577-1578.	1.9	7
41	Seven novel <i>COL7A1</i> mutations identified in patients with recessive dystrophic epidermolysis bullosa from Mexico. <i>Clinical and Experimental Dermatology</i> , 2018, 43, 579-584.	1.3	6
42	The use of rituximab as an adjuvant in the treatment of oral pemphigus vulgaris. <i>Journal of Oral Pathology and Medicine</i> , 2020, 49, 91-95.	2.7	6
43	Clinical guidelines for the use of adjuvant triamcinolone acetonide injections in oro-pharyngeal pemphigus vulgaris: the oral medicine point of view. <i>Journal of Oral Pathology and Medicine</i> , 2011, 40, 359-360.	2.7	5
44	Oral plasmablastic lymphoma in an HIV-positive patient with an unusual survival rate. <i>Infection</i> , 2013, 41, 301-302.	4.7	5
45	Dysgeusia: An Atypical and Neglected Psychiatric Symptom Induced by Fibrillary Astrocytoma. <i>American Journal of Medicine</i> , 2011, 124, e1-e2.	1.5	4
46	Multiple primary melanomas versus single melanoma of the head and neck. <i>Melanoma Research</i> , 2014, 24, 267-272.	1.2	4
47	Linear immunoglobulin A disease and vancomycin: two real ancestral enemies?. <i>British Journal of Dermatology</i> , 2014, 171, 1248-1253.	1.5	4
48	Oral Dysesthesia. , 2019, , 2081-2105.		4
49	Oral Dysesthesia. , 2018, , 1-25.		4
50	“The discomfort is still there, but I do not care much about it!” The Therapeutic Role of the Transference Relationship between the Patient Suffering from Complex Oral Sensitivity Disorder and the Oral Health-care Provider. <i>American Journal of Oral Medicine</i> , 2016, 2, 11-20.	0.2	4
51	Delayed immunologic evidence in pemphigus vulgaris. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2009, 23, 1092-1093.	2.4	3
52	Oral field cancerization: Figure 1:. <i>Cmaj</i> , 2011, 183, 1622-1622.	2.0	3
53	Vitiligo-like hypopigmentation and metastatic melanoma of unknown primary site: friends or foes?. <i>Medical Oncology</i> , 2012, 29, 2963-2965.	2.5	3
54	Sleep quality and disturbances in patients with dystrophic epidermolysis bullosa. <i>Dermatologica Sinica</i> , 2018, 36, 1-7.	0.5	3

#	ARTICLE	IF	CITATIONS
55	Gastric diffuse large B-cell lymphoma (DLBCL) exhibiting oral acanthosis nigricans and tripe palms. <i>Digestive and Liver Disease</i> , 2009, 41, 766-768.	0.9	2
56	Genotype-phenotype correlation in Mexican patients with dystrophic epidermolysis bullosa. <i>International Journal of Oral and Maxillofacial Surgery</i> , 2014, 43, 491-497.	1.5	2
57	Evaluation of internal consistency of the epidermolysis bullosa oropharyngeal severity score (EBOS). <i>Acta Odontologica Scandinavica</i> , 2015, 73, 156-160.	1.6	2
58	Cetrimide-induced oral mucositis: an unusual adverse drug reaction. <i>European Journal of Clinical Pharmacology</i> , 2016, 72, 1415-1416.	1.9	2
59	Escalating dose of adalimumab as monotherapy to treat unusual giant and refractory oral-pharyngeal ulcerations in Crohn's disease. <i>Dermatologic Therapy</i> , 2019, 32, e12868.	1.7	2
60	Sunitinib Adverse Event: Oral Bullous and Lichenoid Mucositis. <i>Annals of Pharmacotherapy</i> , 2009, 43, 546-547.	1.9	2
61	Oral Dysesthesia. , 2017, , 1-26.		0
62	Immunocytometric Analysis of Oral Pemphigus vulgaris Patients after Treatment with Rituximab as Adjuvant. <i>Biomolecules</i> , 2021, 11, 1634.	4.0	0